KORU Medical Systems, Inc. - KRMD STOCK NEWS

KORU Medical Systems (NASDAQ: KRMD) has announced that it will report its first quarter 2023 financial results on May 4, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide updates on corporate developments. The call can be accessed by dialing (800)-734-8507 for U.S. participants, or (212)-231-2925 for international calls, using conference ID: 22026692. A live and archived webcast will also be available on the company’s website. KORU Medical focuses on innovative subcutaneous drug delivery systems designed to enhance patient quality of life, with products like the FREEDOM Syringe Infusion System.

KORU Medical Systems, Inc. (NASDAQ: KRMD) reported strong financial results for Q4 and the full year 2022, achieving a 13% increase in net revenue for Q4 to $7.3 million and 19% growth for the year, totaling $27.9 million. The company saw significant growth in its Novel Therapies business, with revenues skyrocketing 259.9% in Q4, thanks to new collaborations. Although the gross profit increased by 6.4%, it dropped as a percentage of revenue to 55.5% due to rising manufacturing costs. The company anticipates 2023 revenue between $32.5 million and $33.5 million, representing a 17-20% growth.

KORU Medical Systems (NASDAQ: KRMD) announced it will report its fourth quarter and full year 2022 financial results on March 8, 2023, at 4:30 p.m. ET. A conference call and webcast will follow to discuss the results and provide a corporate update. The company's product line includes the FREEDOM Syringe Infusion System, which supports patient home care with innovative drug delivery solutions. Investors can access the call by dialing the provided numbers for the U.S., Canada, and international callers, or via the archived webcast on the company’s website.

KORU Medical Systems, Inc. (NASDAQ: KRMD) has announced a development agreement with a pharmaceutical company to enhance its Freedom Infusion System for subcutaneous immunoglobulin therapy using prefilled syringes. This adaptation aims to facilitate home drug delivery for patients, as prefilled syringes are preferred for their ease of use. The Freedom Infusion System is the only approved system for this application. While the financial terms of the agreement remain undisclosed, the partnership is seen as a significant step towards expanding the number of FDA-approved therapies available for patients globally.

KORU Medical Systems (NASDAQ: KRMD), a medical technology company, announced its participation in two investor conferences on November 17, 2022. The management will present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum at 11:30 am EST, with a live and archived webcast available on their website. They will also attend the 13th Annual Craig-Hallum Alpha Select Conference on the same day. KORU Medical specializes in innovative subcutaneous drug delivery systems aimed at improving patient quality of life.

KORU Medical Systems (NASDAQ: KRMD) reported a strong third quarter for 2022, achieving net sales of $7.8 million, a 28.5% increase year-over-year. This growth was supported by a 46.8% rise in international core sales and a remarkable 251.9% increase in novel therapies. The company raised its full-year revenue guidance to $27.5-$28.0 million and improved its gross margin to 55.7%. However, operating expenses rose to $5.9 million, leading to a net loss of $1.2 million, compared to $1.1 million in the prior year. Cash reserves stood at $16.4 million.

KORU Medical Systems (NASDAQ: KRMD) has progressed its partnership with Kira Pharmaceuticals, expanding their agreement to include three new indications for Phase II studies of Kira's KP-104 program. The conditions target over 150,000 patients in the U.S. with nephrology and hematology conditions. Kira selected KORU for its proven subcutaneous therapeutic solutions, which allow treatments to be administered at home. This partnership reflects KORU's commitment to enhancing its novel therapies pipeline and improving patient care worldwide.

KORU Medical Systems (NASDAQ: KRMD) will report its third quarter 2022 financial results on November 9, 2022, at 4:30 p.m. ET. Management will host a conference call to discuss results and updates. The company is known for its innovative home infusion solutions, including the FREEDOM Syringe Infusion System. Interested parties can access the call at (877)-407-0784 for U.S. callers or (201)-689-8560 for international participants, using conference ID 13732861. Full details available on their website.

KORU Medical Systems (NASDAQ: KRMD) announced its participation in significant industry conferences: the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference on October 18-19 in Palm Springs, California, and the 12th Annual Partnership Opportunities in Drug Delivery (PODD) on October 24-25 in Boston, Massachusetts. KORU Medical aims to enhance its presence in the growing subcutaneous market, focusing on pre-filled syringes and novel therapies. CEO Linda Tharby emphasized the importance of these events in advancing the company's strategic goals.